Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Neoplasm, Residual × isatuximab × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Multiple Myeloma 25 Renal Insufficiency 3 Recurrence 3 Neoplasms, Plasma Cell 3 Neoplasms 3 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2 Paraproteinemias 2 Neoplasms by Histologic Type 2 Hematologic Diseases 2 Blood Protein Disorders 2 Smoldering Multiple Myeloma 1 Purpura 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Neoplasm, Residual 1 Nausea 1 Natural Killer/T-cell Lymphoma 1 Monoclonal Gammopathy of Undetermined Significance 1 Macroglossia 1 Lymphoma, Non-Hodgkin 1 Lymphoma 1 Lymphadenopathy 1 Leukemia, Plasma Cell 1 Leukemia, Myeloid, Acute 1 Leukemia 1 Immunoglobulin Light-chain Amyloidosis 1 Hodgkin Disease 1 Hepatomegaly 1 Hematologic Neoplasms 1 Gastrointestinal Hemorrhage 1 Diarrhea 1

Interventions

blinatumomab 7 Cyclophosphamide 6 Rituximab 5 Lenalidomide 5 Dexamethasone 5 Azacitidine 5 venetoclax 4 fludarabine 4 fludarabine phosphate 3 Cytarabine 3 tislelizumab 2 thymoglobulin 2 obinutuzumab 2 daratumumab 2 Whole-Body Irradiation 2 N,N-dicyclohexyl-isoborneol-10-sulfonamide 2 Methotrexate 2 Melphalan 2 Immunotherapy 2 Imatinib Mesylate 2 Docetaxel 2 Decitabine 2 Clofarabine 2 Cladribine 2 Calcium Dobesilate 2 Busulfan 2 treosulfan 1 trastuzumab deruxtecan 1 tisagenlecleucel 1 talquetamab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05690984 2026-03-16

EMAT

Medical College of Wisconsin

Phase 2 Active not recruiting

Multiple Myeloma, Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon ⚡